March 29, 2018
After World TB Day, High Expectations for Action
A message from Mel Spigelman, TB Alliance President and CEO
March 6, 2018
Nancy Miller-Rich Joins TB Alliance Board of Directors
Miller-Rich has 35 years of experience in the pharmaceutical industry, including global business development at Merck Pharmaceuticals
February 7, 2018
ZeNix Clinical Trial Announced
New trial evaluates whether the efficacy of the BPaL drug regimen can be maintained with reduced toxicity
November 17, 2017
Ending TB Means Investing in R&D
Joint statement from Aeras, FIND, TB Alliance, and TBVI
November 6, 2017
Ariel Pablos-Méndez Joins TB Alliance Board of Directors
Dr. Pablos-Méndez brings decades of experience in strategies to improve the lives of the poor and most vulnerable people in the world
October 30, 2017
TB Alliance Statement on WHO’s Global Tuberculosis Report 2017
TB continues to be the leading cause of death from a single infectious agent worldwide.
October 10, 2017
TB Alliance Moves Two Novel Tuberculosis Drugs into Human Trials
TBA-7371 and Sutezolid Help Fill Sparse Pipeline of New Antibiotics Against a Disease That Grows Increasingly Resistant to Older Drugs
September 27, 2017
TB Alliance Endorses WHO Designation of TB as a “Global Priority Pathogen”
New reports call for increased research and development funding
August 31, 2017
WHO Prequalifies Childhood TB Medicine
TB Alliance led efforts to develop improved medicines for children with tuberculosis
July 10, 2017